#1
|
|||
|
|||
Ãèíåêîìàñòèÿ - ïðè÷èíû?
40 ëåò. Çàíèìàþñü ñïîðòîì.  98 ãîäó íà ôîíå óïîòðåáëåíèÿ òåñòîñòåðîíîâ è íàíäðîëîíîâ îáðàçîâàëàñü óçëîâàÿ ãèíåêîìàñòèÿ ñ ïðàâîé ñòîðîíû.  2000 ãîäó ïðîîïåðèðîâàíà. Ïðè ïîñëåäóþùåì ïðèìåíåíèè àíäðîãåíîâ ÷àñòè÷íî âíîâü âîçíèêëà, â ïåðèîäû áåç àíäðîãåíîâ - íàïîëîâèíó ðàññàñûâàåòñÿ è çàìèðàåò, íå ïðîãðåññèðóåò. Ïî ñîáñòâåííûì îùóùåíèÿì ïðè÷èíà - ïðîãåñòàãåííàÿ àêòèâíîñòü íàíäðîëîíîâ âîñíîâíîì, â ìåíüøåé ñòåïåíè àðîìàòèçàöèÿ äëèííûõ ýôèðîâ òåñòîñòåðîíà è ïåðåãðóæåííîñòü ïå÷åíè.
2 ìåñÿöà íàçàä, ñïóñòÿ 6 ìåñ. ïîñëå îêîí÷àíèÿ î÷åðåäíîé ñòåðîèäíîé "òåðàïèè" óæå ñ ëåâîé ñòîðîíû âîçíèêëî óïëîòíåíèå, ðàçìåðîì ñ ãîðîøèíó, òî÷ü â òî÷ü êàê êîãäà ñ ïðàâîé íà÷èíàëîñü. Ïðè ýòîì îáðàçîâàíèå ñ ïðàâîé ñòîðîíû ñîâñåì íå áåñïîêîèò è íàõîäèòñÿ â "íåàêòèâíîì" ñîñòîÿíèè. Àíàëèçû: Ïðîãåñòåðîí 0,33 íã/ìë (ðåô.çí. 0,00-0,75) Òåñòîñòåðîí 2,88 íã/ìë (ðåô.çí. 2,86-15,11) Ëà 2,30 ìÌÅä/ìë (ðåô.çí. 0,80-7,60) Ïðîëàêòèí 4,38 íã/ìë (ðåô.çí. 2,50-17,00) ÔÑà 2,30 ìÌÅä/ìë (ðåô.çí. 0,70-11,10) Òàê æå ïàðó ìåñÿöåâ íàçàä ó ìåíÿ íà÷àëîñü ñåçîííîå îáîñòðåíèå õðîíè÷åñêèõ õîëåöèñòèòà ñ ïàíêðåàòèòîì, ÀëÒ áûëî 0,8. Ñåé÷àñ òðàíñàìèíàçû â íîðìå. Ýíäîêðèíîëîã â ïîëèêëèíèêå ïðîïèñàë õëîðèñòûé êàëüöèé ïîäêîæíî â ïðåäïëå÷üå )ïðîáëåìà òîëüêî â òîì, ÷òî åãî äàâíî íèêòî íå äåëàåò) îò 0,2 êóá äî 2-õ ãîðêîé è îáðàòíî + Â1 è Â6 ÷åðåç äåíü. Ïðàâèëüíî ëè íàçíà÷åííîå ëå÷åíèå? Íå äîáàâèòü ëè ñþäà èíãèáèòîðîâ àðîìàòàçû (àðèìèäåêñ, àðîìàçèí) èëè àíòèýñòðîãåíîâ (òàìîêñèôåí, êëîìèôåí öèòðàò)?  êàêèõ äîçèðîâêàõ? Êàêîâû ìîãóò áûòü ïðè÷èíû âîçíèêíîâåíèÿ? |
#2
|
||||
|
||||
Ñêàæèòå, êàêàÿ ñèëà çàñòàâëÿåò âàñ ââîäèòü àíäðîãåíû è àíàáîëèêè, ïîëó÷àòü îæèäàåìûå îñëîæíåíèÿ, ñäàâàòü íèêîìó íåíóæíûå àíàëèçû è ïðîâîäèòü áåññìûñëåííûå ÿêîáû ëå÷åáíûå ìåðîïðèÿòèÿ? Çà÷åì Âàì òåîðèÿ âîïðîñà- êîãäà ïðàêòèêà ñòîëü ÿñíà?
__________________
Ã.À. Ìåëüíè÷åíêî |
#3
|
||||
|
||||
Òî ÷òî õëîðèñòûé êàëüöèé äàâíî íèêòî íå äåëàåò ïîäêîæíî - ýòî íå ïðîáëåìà à Ùàñòüå...
|
#4
|
|||
|
|||
Öèòàòà:
Îòâåòüòå ìíå íà âîïðîñ: êàêàÿ ñèëà çàñòàâëÿåò ìèëëèîíû ðîññèÿí âûïèâàòü ïî ëèòðó âîäêè, êîãäà â ó÷åáíèêå ïî ïàòàíàòîìèè â ãëàâå "îòðàâëåíèÿ" ÷åðíûì ïî áåëîìó íàïèñàíî, ÷òî 200-300 ìë. ñïèðòà - ñìåðòåëüíî äëÿ ÷åëîâåêà, âåñîì 80 êã??? Ïî÷åìó ýòîò ôàêò Âàñ íå çàäåâàåò? Êàê è 54 òûñ. óìåðøèõ â ãîä îò îñòðîãî àëêîãîëüíîãî îòðàâëåíÿ? À ÿ, êàê íè ñòðàííî, ïåðåæèë áîëüøóþ ïîëîâèíó ñâîèõ îäíîêëàññíèêîâ. Êàêàÿ ñèëà çàñòàâëÿåò àëüïèíèñòîâ ïåðåòüñÿ â ãîðû? Íà îäíîì Ýâåðåñòå 20-30 òðóïîâ â ãîä, íå ãîâîðÿ óæå îá àìïóòàíòàõ ïîñëå îòìòðîæåíèÿ... Ïî÷åìó ýòî Âàñ íå âîçìóùàåò? Ðàáîòà ó ìåíÿ òàêàÿ. Åñëè Âû íå çíàåòå, ÷òî ñïîðò òîæå áûâåò ðàáîòîé. Ïî Âàøåìó, øàõòåð ëåçåò â øàõòó, ÷òîáû ïîëó÷èòü "îæèäàåìûå îñëîæíåíèÿ" - ñèëèêîç è ïð. ... Æåëàíèå ïîïèíàòü êîãî-òî? Âîí îëèìïèàäà èäåò - ìîæåòå ïèíàòü âñåõ, íå ïåðåáèðàÿ. Íå îøèáåòåñü. |
#5
|
|||
|
|||
Öèòàòà:
|
#6
|
|||
|
|||
Ïî ïîâîäó ñïîðòà õîðîøî ãîâîðèë îäèí èçâåñòíûé â ñåòè êàðäèîàðèòìîëîã: "Åñëè ÷åëîâåê õî÷åò ñåáå îòðóáèòü ðóêó, ÿ êàê âðà÷ íå áóäó åìó ïîìîãàòü".
Íà ìîé âçãëÿä, ñàìî ïîíÿòèå "ñïîðòèâíàÿ ìåäèöèíà" èç ñåðèè "òðîãàòåëüíûå ìàðøè". |
#7
|
||||
|
||||
Íäà, äîïëûëè.
Óâàæàåìûé iso! Äàâàéòå äîãîâîðèìñÿ î äâóõ âåùàõ: 1. Íèêòî çäåñü íà ñàéòå Âàì àíàáîëèêè è ïðî÷àÿ íå íàçíà÷àë. Êòî ýòî ñäåëàë - Âàì âèäíåå. Ñïðàøèâàòü, ÷òî äåëàòü ñ ïîñëåäñòâèÿìè, ëîãè÷íåå ó òîãî, êòî èíèöèèðîâàë ïðèåì ïðåïàðàòà, âåðîÿòíî, ïðåäóïðåäèâ î ïîñëåäñòâèÿõ. Åñëè î ïîñëåäñòâèÿõ Âàñ íå ïðåäóïðåäèëè - ëîãè÷íåå åìó æå íàáèòü ôýéñ. 2. Æåëàíèå ïîïèíàòü â Âàøåì ïîñòå çàìåòíî êóäà áîëüøå, íåïîíÿòíî, ïî÷åìó Âû äëÿ ïèíàíèÿ ïðèøëè ñþäà. Íè îäèí èç çäåñü êîíñóëüòèðóþùèõ âðà÷åé íå íàçíà÷èò àíàáîëèêè ñïîðòñìåíàì - ïîèùèòå íà ôîðóìå, íàéäåòå òåìû, ãäå ýòè âîïðîñû ïîäíèìàëèñü. Ïîýòîìó ïðèìèòå êàê äàííîñòü - çäåñü Âàì áóäóò ñîâåòîâàòü òî, ÷òî îäíîçíà÷íî ïîëåçíî äëÿ Âàøåãî çäîðîâüÿ. Òî åñòü - îòìåíó àíàáîëèêîâ è ñòåðîèäîâ. Åñëè Âàì ýòî ïî÷åìó- ëèáî íå íóæíî, ýòî Âàø âûáîð. Ïðî òî, ÷òî äðóãèå òîæå ïüþò, ìîæåòå íå ðàññêàçûâàòü - ýòî íèêàê íå îïðàâäûâàåò Âàø âûáîð âðåäèòü ñåáå. È ïîñòàðàéòåñü îòíåñòèñü ñ áëàãîäàðíîñòüþ ê çàáîòå, êîòîðóþ íåçíàêîìûå ëþäè ïðîÿâèëè î Âàøåì çäîðîâüå. Õàìñòâî çäåñü íàêàçóåìî.
__________________
Lead, follow, or get out of the way. — Thomas Paine |
|
#8
|
|||
|
|||
Äåéñòâèòåëüíî, ïðèïëûëè. Ñîãëàñåí.
Óâ. îòâå÷àþùèå. ß âðîäå íèêîãî íå îáâèíÿë â íàçíà÷åíèè ìíå ñòåðîèäîâ. Íå íó÷æíî ïåðåêðó÷èâàòü. ß ñïðîñèë ñîâåòà. À õàìñòâî - ýòî îòâå÷àòü íå íà âîïðîñ ïî ñóùåñòâó, à íà÷èíàòü ðàññóæäåíèÿ à "çà÷åì ýòî íóæíî, äåáèë ïîëó÷èë òî, ê ÷åìó ñòðåìèëñÿ". Òàê ÷òî îáâèíåíèå â õàìñòâå - íåñêîëüêî íå ïî àäðåñó. ×åëîâåêó, îòðóáèâøåìó ñåáå ðóêó, òåì íå ìåíåå ôîðìèðóþò êóëüòþ. È àëêàøàì íå îòâå÷àþò - èäè, ïåé äàëüøå. À ìíå ñðàçó ãðîçÿò íàêàçàíèåì!!! Ïîðàçèòåëüíî, ãîñïîäà Ãèïïîêðàòû... Ïîêà ÿ íå çàìåòèë, ÷òî êòî-òî ïðîÿâèë îáî ìíå çàáîòó. Ñîâåò îòìåíèòü àíàáîëèêè î÷åíü öåíåí. Òåì áîëåå, ÷òî îíè îòìåíåíû áîëåå ïîëóãîäà íàçàä è ïðîâåäåíà ñîîòâåòñòâóþùàÿ âîññòàíîâèòåëüíàÿ òåðàïèÿ. Ñîâåòîâ èëè ïðåäïîëîæåíèé, îäíîçíà÷íî ïîëåçíûõ ìíå â äàííîé ñèòóàöèè ÿ ïîêà íå íàáëþäàþ. È òðîãàòåëüíîé çàáîòû î ñâîåì çäîðîâå, î êîòîðîé çäåñü óïîìÿíóòî, òîæå íå âèæó. À íàáëþäàþ ëèøü òî, ÷òî íàáëþäàþ óæå 20 ëåò è äîëæåí áûë áû óæå ïðèâûêíóòü. Áèòü ìîðäó òåì, êòî ìåíÿ ïðèâåë â ñïîðò íå áóäó. ß íå áóäó áèòü ìîðäû ëþäÿì, áëàãîäàðÿ êîòîðûì ÿ íå ñòàë àëêàøîì, íàðêîìàíîì è ïðåñòóïíèêîì. Õîòÿ ê ýòîìó áûëà ïðÿìàÿ äîðîãà. Íåò æåëàíèÿ îòâå÷àòü ïî òåìå? Òîãäà, îáû÷íî, ìîë÷àò. ß íå ïðîøó Âàñ äàâàòü îöåíêó ìîåìó âûáîðó. Íå õîòèòå îòâå÷àòü? Òàê è ñêàæèòå: "íå õîòèì, çàêðûâàåì òåìó, ýòî ïðîòèâîðå÷èò êîíöåïöèè ôîðóìà". Ã-íó Ðîäèîíîâó: "ñïîðòèâíàÿ ìåäèöèíà" - ýòî, íàïðèìåð, ëå÷åíèå ñïåöèôè÷åñêèõ ñïîðòèâíûõ òðàâì (ëîêîòü òåííèñèñòà, êîëåíî ôóòáîëèñòà è ïð.). Âû, íàâåðíîå, õîòåëè ñêàçàòü "ñïîðòèâíàÿ ôàðìàêîëîãèÿ". Òåì íå ìåíåå, îíà ñóùåñòâóåò - è êàê íàïðàâëåíèå â íàóêå è êàê áèçíåñ. À íîíñåíñîâ â ñîâðåìåííîì ìèðå ïðåäîñòàòî÷íî, áåçóñëîâíî. Âñå-òàêè âûïîëíèòå ìîþ ïðîñüáó - ñíèçîéäèòå äî âûñêàçûâàíèÿ Âàøèõ ìíåíèé. Ìíåíèÿ òåõ, êòî "ðåêîìåíäîâàë ìíå àíàáîëèêè" ÿ ñïðîñèë â ïåðâóþ î÷åðåäü. Èíòåðåñóåò ìíåíèå îôèöèàëüíîé ìåäèöèíû. Çàðàíåå ïðîøó ïðîùåíèÿ, åñëè ìîè âîïðîñû íåêîððåêòíû è åñëè ÿ êîãî-òî íåçàñëóæåííî îáèäåë. |
#9
|
||||
|
||||
Öèòàòà:
À õëîðèñòûé êàëüöèé ââîäèòñÿ òîëüêî âíóòðèâåííî. Ïðè ïîäêîæíîì ââåäåíèè âûçûâàåò íåêðîç òêàíåé. |
#10
|
|||
|
|||
Öèòàòà:
Ëàäíî, ïðîåõàëè... |
#11
|
||||
|
||||
Ïîçâîëüòå íàïîìíèòü Âàø âîïðîñ. Ñ Âûäåëåíèåì êëþ÷åâûõ ìîìåíòîâ.
Öèòàòà:
Ïðàâèëüíî ëè íàçíà÷åííîå Âàì ëå÷åíèå? Íåò. Ðåøåíèå âîïðîñà î íàçíà÷åíèè àäåêâàòíîãî ëå÷åíèÿ îñòàåòñÿ çà âðà÷îì. Åñëè Âàø âðà÷ íå êîìïåòåíòåí, íàéäèòå äðóãîãî âðà÷à. Íî ñàìîëå÷åíèåì áîëüøå íå çàíèìàéòåñü. Õâàòèò óæå, èòàê äîèãðàëèñü. |
#12
|
||||
|
||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
|
#13
|
||||
|
||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Âñåì áîëüøîå ñïàñèáî çà îòâåòû. È âñå òàêè æäó êîìïåòåíòíûõ ìíåíèé ëþäåé, ïëîòíî ñòàëêèâàâøèõñÿ ñ ïîäîáíûìè àíàìíåçàìè. |
#14
|
|||
|
|||
Öèòàòà:
Eur J Clin Pharmacol. 2003 Nov;59(8-9):571-7. Epub 2003 Sep 12. The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eklof AC, Thurelius AM, Garle M, Rane A, Sjoqvist F. Department of Clinical Pharmacology, Huddinge University Hospital, 14185 Stockholm, Sweden. With the support of the Swedish National Institute of Health a national information service was started in 1993 aiming to capture the abuse of doping agents in the general public. It was organized as a telephone service, called the Anti-Doping Hot-Line, from our department and managed by trained nurses co-operating with clinical pharmacologists. Important information collected about all callers (anonymous) was: date of call, its origin, category of caller, doping experience and main question being asked. Abusers were asked about their age, sex, affiliation, abused drug(s), duration of abuse, habit of administration and adverse reactions (ADRs). Between October 1993 and December 2000 25,835 calls were received with a peak during spring and autumn. Most calls (12,400) came from non-abusers, 60% being males. Callers connected with gyms represented the largest group (30%). Most calls about specific drugs concerned anabolic androgenic steroids (AAS). Other drugs or products included ephedrine, clenbuterol and creatine. The most commonly abused anabolic steroids were testosterone, nandrolone-decanoate, methandienone and stanozolol. The ten most commonly reported ADRs of AAS were aggressiveness (835), depression (829), acne (770), gynecomastia (637), anxiousness (637), potency problems (413), testicular atrophy (404), sleep disorders (328), fluid retention (318) and mood disturbances (302). Female side effects included menstruation disturbances, hair growth in the face, lower voice and enlarged clitoris. During the period 1996-200, totally 4339 persons reported about 10,800 side effects. This figure should be compared with the very low number of ADRs (27) reported by prescribers to the Swedish ADR committee during the same period. Abuse of doping agents appears to be a new public health problem that needs detection, medical care and prevention. Êðàòêîå ðåçþìå (ïî ïðàâèëàì ôîðóìà ÿ äîëæåí ïåðåâåñòè íà ðóññêèé ÿçûê ñìûòûé ñêðûñë àíãëèéñêîãî èñòî÷íèêà): Ïî÷òè 26 òûñÿ÷ ãîðå-ñïîðòñìåíîâ â ïåðèîä ñ 1993 ïî 2000 ã çâîíèëè â øâåöêóþ àíòèäîïèíãîâóþ "ãîðÿ÷óþ ëèíèþ". Èç íèõ 637 (ýòî 2,5%) æàëîâàëèñü íà ãèíåêîìàñòèþ.  "äåñÿòêó" îñíîâíûõ ïîáî÷íûõ ýôôåêòîâ àíàáîëèêîâ òàêæå âõîäèëè àãðåññèâíîñòü, äåïðåññèÿ, óãðè, òðåâîæíîñòü, ïðîáëåìû ñ ïîòåíöèåé, àòðîôèÿ ÿè÷åê, íåðóøåíèå ñíà, çàäåðæêà æèäêîñòè è ïëîõîå íàñòðîåíèå. |
#15
|
|||
|
|||
Öèòàòà:
|